Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis. PERSIAN trial: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results